The AMR Industry Alliance’s Commitments
We measure and drive the life-sciences industry progress to curb antimicrobial resistance in four different areas:
research & science
Declaration – January 2016
Signatories: Over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations have signed the Declaration.
- Work to reduce the development of AMR
- Invest in R&D to meet public health needs with new innovative diagnostics & treatments
- Improve access to existing high-quality antibiotics and ensuring that new ones are available to all
Roadmap – September 2016
Signatories: A sub-set of companies committed to the Industry Declaration: 13 companies of the 100+ Alliance members are committed to the Roadmap.
Commitments: The Roadmap lays out four commitments to reduce AMR by 2020: reduce the environmental impact of manufacturing, addressing inappropriate use, improving global access and developing a broad R&D ecosystem.